Anthony C Vernon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1103267/publications.pdf

Version: 2024-02-01

73 papers 2,510 citations

218677 26 h-index 223800 46 g-index

86 all docs 86 docs citations

86 times ranked 3926 citing authors

#	Article	IF	CITATIONS
1	Brain microglia in psychiatric disorders. Lancet Psychiatry,the, 2017, 4, 563-572.	7.4	208
2	Effect of Chronic Antipsychotic Treatment on Brain Structure: A Serial Magnetic Resonance Imaging Study with Ex Vivo and Postmortem Confirmation. Biological Psychiatry, 2011, 69, 936-944.	1.3	166
3	Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nature Communications, 2020, 11 , 246.	12.8	148
4	Schizophrenia and Influenza at the Centenary of the 1918-1919 Spanish Influenza Pandemic: Mechanisms of Psychosis Risk. Frontiers in Psychiatry, 2020, 11, 72.	2.6	138
5	Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease. BMC Neuroscience, 2010, $11,1.$	1.9	137
6	Contrasting Effects of Haloperidol and Lithium on Rodent Brain Structure: A Magnetic Resonance Imaging Study with Postmortem Confirmation. Biological Psychiatry, 2012, 71, 855-863.	1.3	113
7	Reduced Cortical Volume and Elevated Astrocyte Density in Rats Chronically Treated With Antipsychotic Drugs—Linking Magnetic Resonance Imaging Findings to Cellular Pathology. Biological Psychiatry, 2014, 75, 982-990.	1.3	85
8	Behavioral, neuroanatomical, and molecular correlates of resilience and susceptibility to maternal immune activation. Molecular Psychiatry, 2021, 26, 396-410.	7.9	80
9	Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses. European Neuropsychopharmacology, 2015, 25, 2098-2107.	0.7	77
10	Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. European Journal of Neuroscience, 2005, 22, 1799-1806.	2.6	71
11	Evolution of a maternal immune activation (mIA) model in rats: Early developmental effects. Brain, Behavior, and Immunity, 2019, 75, 48-59.	4.1	66
12	Evolution of structural abnormalities in the rat brain following in utero exposure to maternal immune activation: A longitudinal in vivo MRI study. Brain, Behavior, and Immunity, 2017, 63, 50-59.	4.1	64
13	Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability. Neuroscience and Biobehavioral Reviews, 2018, 85, 146-159.	6.1	63
14	Interferon-l̂3 signaling in human iPSC–derived neurons recapitulates neurodevelopmental disorder phenotypes. Science Advances, 2020, 6, eaay9506.	10.3	56
15	Whole-brain ex-vivo quantitative MRI of the cuprizone mouse model. PeerJ, 2016, 4, e2632.	2.0	53
16	Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6â€hydroxydopamine toxicity ⟨i⟩in vivo⟨/i⟩. Journal of Neurochemistry, 2007, 103, 1075-1091.	3.9	49
17	The brain's code and its canonical computational motifs. From sensory cortex to the default mode network: A multi-scale model of brain function in health and disease. Neuroscience and Biobehavioral Reviews, 2015, 55, 211-222.	6.1	48
18	Neurorestoration induced by the <scp>HDAC</scp> inhibitor sodium valproate in the lactacystin model of <scp>P</scp> arkinson's is associated with histone acetylation and upâ€regulation of neurotrophic factors. British Journal of Pharmacology, 2015, 172, 4200-4215.	5.4	46

#	Article	IF	CITATIONS
19	Evolution of Extra-Nigral Damage Predicts Behavioural Deficits in a Rat Proteasome Inhibitor Model of Parkinson's Disease. PLoS ONE, 2011, 6, e17269.	2.5	44
20	The Psychiatric Risk Gene NT5C2 Regulates Adenosine Monophosphate-Activated Protein Kinase Signaling and Protein Translation in Human Neural Progenitor Cells. Biological Psychiatry, 2019, 86, 120-130.	1.3	42
21	Neuroimaging for Lewy body disease: Is the in vivo molecular imaging of α-synuclein neuropathology required and feasible?. Brain Research Reviews, 2010, 65, 28-55.	9.0	39
22	From early adversities to immune activation in psychiatric disorders: the role of the sympathetic nervous system. Clinical and Experimental Immunology, 2019, 197, 319-328.	2.6	34
23	Selective Activation of Group III Metabotropic Glutamate Receptors by l-(+)-2-Amino-4-phosphonobutryic Acid Protects the Nigrostriatal System against 6-Hydroxydopamine Toxicity in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 397-409.	2.5	32
24	Longitudinal in vivo maturational changes of metabolites in the prefrontal cortex of rats exposed to polyinosinic–polycytidylic acid in utero. European Neuropsychopharmacology, 2015, 25, 2210-2220.	0.7	32
25	Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies. Neuroscience and Biobehavioral Reviews, 2017, 76, 317-335.	6.1	31
26	Planar Airy beam light-sheet for two-photon microscopy. Biomedical Optics Express, 2020, 11, 3927.	2.9	31
27	Simultaneous effects on parvalbumin-positive interneuron and dopaminergic system development in a transgenic rat model for sporadic schizophrenia. Scientific Reports, 2016, 6, 34946.	3.3	27
28	An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers. Human Brain Mapping, 2018, 39, 319-331.	3.6	27
29	The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. Translational Psychiatry, 2021, 11, 393.	4.8	27
30	Effects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System. CNS Drugs, 2020, 34, 1229-1251.	5.9	26
31	Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways. Translational Psychiatry, 2013, 3, e208-e208.	4.8	24
32	Systemic α-synuclein injection triggers selective neuronal pathology as seen in patients with Parkinson's disease. Molecular Psychiatry, 2021, 26, 556-567.	7.9	24
33	Brain Morphometry and the Neurobiology of Levodopa-Induced Dyskinesias: Current Knowledge and Future Potential for Translational Pre-Clinical Neuroimaging Studies. Frontiers in Neurology, 2014, 5, 95.	2.4	23
34	Preclinical animal models of mental illnesses to translate findings from the bench to the bedside: Molecular brain mechanisms and peripheral biomarkers associated to early life stress or immune challenges. European Neuropsychopharmacology, 2022, 58, 55-79.	0.7	22
35	Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model. NeuroReport, 2008, 19, 475-478.	1.2	21
36	Maternal immune activation primes deficiencies in adult hippocampal neurogenesis. Brain, Behavior, and Immunity, 2021, 97, 410-422.	4.1	20

#	Article	IF	Citations
37	Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease. Parkinson's Disease, 2010, 2010, 1-12.	1.1	19
38	Normalizing the Abnormal: Do Antipsychotic Drugs Push the Cortex Into an Unsustainable Metabolic Envelope? Schizophrenia Bulletin, 2020, 46, 484-495.	4.3	17
39	Viewpoint European COVID-19 exit strategy for people with severe mental disorders: Too little, but not yet too late. Brain, Behavior, and Immunity, 2021, 94, 15-17.	4.1	17
40	Do levodopa treatments modify the morphology of the parkinsonian brain?. Movement Disorders, 2012, 27, 166-167.	3.9	16
41	Registration of challenging pre-clinical brain images. Journal of Neuroscience Methods, 2013, 216, 62-77.	2.5	16
42	Striatal Volume Increase After Six Weeks of Selective Dopamine D2/3 Receptor Blockade in First-Episode, Antipsychotic-NaÃ-ve Schizophrenia Patients. Frontiers in Neuroscience, 2020, 14, 484.	2.8	15
43	Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume loss. Psychological Medicine, 2016, 46, 3081-3093.	4.5	14
44	Emerging Developments in Human Induced Pluripotent Stem Cell-Derived Microglia: Implications for Modelling Psychiatric Disorders With a Neurodevelopmental Origin. Frontiers in Psychiatry, 2020, 11, 789.	2.6	14
45	Application of Airy beam light sheet microscopy to examine early neurodevelopmental structures in 3D hiPSC-derived human cortical spheroids. Molecular Autism, 2021, 12, 4.	4.9	14
46	Selective activation of metabotropic glutamate receptor 7 induces inhibition of cellular proliferation and promotes astrocyte differentiation of ventral mesencephalon human neural stem/progenitor cells. Neurochemistry International, 2011, 59, 421-431.	3.8	12
47	Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue. Psychoneuroendocrinology, 2018, 95, 28-33.	2.7	12
48	Global brain volume reductions in a sub-chronic phencyclidine animal model for schizophrenia and their relationship to recognition memory. Journal of Psychopharmacology, 2019, 33, 1274-1287.	4.0	12
49	Region-specific and dose-specific effects of chronic haloperidol exposure on [3H]-flumazenil and [3H]-Ro15-4513 GABAA receptor binding sites in the rat brain. European Neuropsychopharmacology, 2020, 41, 106-117.	0.7	12
50	Sexually dimorphic neuroanatomical differences relate to ASD-relevant behavioral outcomes in a maternal autoantibody mouse model. Molecular Psychiatry, 2021, 26, 7530-7537.	7.9	12
51	MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia. Brain Communications, 2021, 3, fcab114.	3.3	11
52	Neuroanatomical and Microglial Alterations in the Striatum of Levodopa-Treated, Dyskinetic Hemi-Parkinsonian Rats. Frontiers in Neuroscience, 2020, 14, 567222.	2.8	10
53	Effects of chronic exposure to haloperidol, olanzapine or lithium on SV2A and NLGN synaptic puncta in the rat frontal cortex. Behavioural Brain Research, 2021, 405, 113203.	2.2	10
54	Characterization of gray matter atrophy following 6-hydroxydopamine lesion of the nigrostriatal system. Neuroscience, 2016, 334, 166-179.	2.3	9

#	Article	lF	CITATIONS
55	Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease. PLoS ONE, 2017, 12, e0180733.	2.5	9
56	Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson's disease. PLoS ONE, 2017, 12, e0172394.	2.5	8
57	Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex Congenita. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	7
58	A unique cerebellar pattern of microglia activation in a mouse model of encephalopathy of prematurity. Glia, 2022, 70, 1699-1719.	4.9	7
59	Attenuated transcriptional response to pro-inflammatory cytokines in schizophrenia hiPSC-derived neural progenitor cells. Brain, Behavior, and Immunity, 2022, 105, 82-97.	4.1	7
60	Mice with Reduced Vesicular Monoamine Storage Content Display Nonmotor Features of Parkinson's Disease: Table 1 Journal of Neuroscience, 2009, 29, 12842-12844.	3.6	6
61	Effects of Lithium on Magnetic Resonance Imaging Signal Might Not Preclude Increases in Brain Volume After Chronic Lithium Treatment. Biological Psychiatry, 2013, 74, e39-e40.	1.3	6
62	GABAA and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for schizophrenia. Neuropsychopharmacology, 2022, 47, 687-695.	5.4	6
63	Mapping the impact of exposure to maternal immune activation on juvenile Wistar rat brain macroand microstructure during early post-natal development. Brain and Neuroscience Advances, 2019, 3, 239821281988308.	3.4	3
64	Functional brain defects in a mouse model of a chromosomal $t(1;11)$ translocation that disrupts DISC1 and confers increased risk of psychiatric illness. Translational Psychiatry, 2021, 11, 135.	4.8	3
65	287. Neuroadaptations to Chronic Ketamine Exposure: A Parallel Human and Mouse MRI Imaging Study. Biological Psychiatry, 2017, 81, S118.	1.3	1
66	Microglia and Psychiatric Disorders. , 2021, , 133-157.		1
67	Transvascular delivery of α-synuclein preformed fibrils, using the RVG9R delivery system, generates α-synuclein pathology in the duodenal myenteric plexus of non-transgenic rats. Molecular Psychiatry, 2021, 26, 365-365.	7.9	1
68	Brain volume in chronic ketamine users $\hat{a} \in \mathbb{C}$ relationship to sub-threshold psychotic symptoms and relevance to schizophrenia. Psychopharmacology, 2021, , 1.	3.1	1
69	Editorial: Cardiovascular and Physical Health in Severe Mental Illness. Frontiers in Psychiatry, 2021, 12, 760250.	2.6	1
70	Non-invasive MR Imaging of Neurodegeneration in a Rodent Model of Parkinson's Disease. Methods in Molecular Biology, 2011, 711, 487-510.	0.9	1
71	Cellular and molecular signatures of in vivo imaging measures of GABAergic neurotransmission in the human brain. Communications Biology, 2022, 5, 372.	4.4	1
72	Reply to: Lithium and the Expanding Brain. Biological Psychiatry, 2012, 72, e19.	1.3	0

ANTHONY C VERNON

#	Article	lF	CITATIONS
73	Corrigendum to: Normalizing the Abnormal: Do Antipsychotic Drugs Push the Cortex Into an Unsustainable Metabolic Envelope?. Schizophrenia Bulletin, 2020, , .	4.3	0